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Abstract
The location of the immunologic response to an allograft is not known with certainty.
However, organized collections of T cells, B cells and antigen presenting cells have been
found in peripheral tissue, in close proximity to organs undergoing rejection.

It is

hypothesized that this tertiary lymphoid tissue may be a location in which activation of
lymphocytes can occur, leading to rejection of an allograft. We report here that in a
splenectomized aly/aly mouse, which is devoid of secondary lymphoid organs and will
normally fail to reject an allograft, the presence of tertiary lymphoid organs is associated
with graft rejection. We additionally find that tertiary lymphoid organs can act as lymph
nodes, and can support effector and memory allograft rejection responses.

It is

demonstrated that ectopic lymphoid tissue in aly/aly mice will support the multiplication
and transformation of transferred naïve CD4 and CD8 T cells into cells that display
phenotypic markers characteristic of effector and memory lymphocytes. These results
demonstrate that ectopic lymphoid tissue is associated with the loss of immunologic
ignorance and is sufficient to enable graft rejection. This suggests that allograft rejection
may take place within ectopic lymphoid tissue, and suggests that techniques to interfere
with the development of this tissue might offer a therapeutic approach to preserving organ
allografts.
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1
INTRODUCTION

Background of Problem
While organ and tissue transplantation holds great promise for the treatment of end-stage
organ disease, immunological rejection of transplanted tissue remains a significant clinical
challenge. In order to stave off rejection, transplant recipients must currently commit to a
lifetime regimen of immunosuppressive drugs. While these pharmaceuticals greatly reduce
the incidence and magnitude of the rejection process, their use comes with many
drawbacks. The drugs suppress the entire systemic immune system, leaving patients open
to opportunistic infection and malignancies. They are expensive, and most importantly,
they fail to completely suppress long-term organ rejection.
Because of these substantial drawbacks of systemic immunologic suppression, any
mechanism that would permit the immune system to remain disinterested in a specific
antigen, such as a grafted organ, while maintaining the system’s natural surveillance and
disease suppression functions, would be highly desirable.
Acute rejection of an allograft depends on the responses of activated CD4 and CD8 T
lymphocytes. Activation of naïve lymphocytes occurs when alloantigen is presented to a
naïve lymphocyte by an antigen-presenting cell, along with coincident signaling through
costimulatory receptors.

Efforts to prevent rejection currently focus primarily on

interruption of these signaling pathways in an effort to inhibit the subsequent activation and
clonal expansion of alloreactive lymphocytes. It also important, however, to understand the
anatomic context in which activation occurs, because if it is possible to interrupt the sites of
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interaction of the cells involved in the adaptive immune response, such that foreign
antigen is not presented to naïve T cells, it may be possible to exploit immunologic
ignorance of grafted tissue, rather than tolerance, as a long-term mechanism permitting
graft survival.

Immunologic Ignorance
Immunologic ignorance is a state in which the immune system remains quiescent because it
is unaware that a particular antigen is present. In such a state, the immune system is not
suppressed, but fully functional, and will freely respond to antigenic stimuli that are
successfully presented. However, if the mechanism of antigen presentation is disrupted,
then the immune system will remain oblivious to the presence of alloreactive tissue. As
long as ignorance is preserved, foreign antigen, including transplanted tissue from
unrelated donors, will remain free of efforts by the immune system to reject the tissue.
However, if normal locations and mechanisms of immune stimulation are reestablished,
ignorance will be broken, and allogeneic tissue will again be subjected to evaluation by the
usual mechanisms of immune alloreactivity.
Zinkernagel has posited a general “antigen-localization dose time” model for immunologic
interactions, which proposes that the localization of antigen with respect to lymphoid tissue
and the time of interaction are prime determinants of the pattern of reactivity towards an
antigen(1). Moderate quantity of antigen, newly presented to a naïve T cell by an antigenpresenting cell in the anatomic context of secondary lymphoid tissues will initiate a
reaction. Antigens that do not reach lymphoid tissues, or do so in insufficient quantity or
interact for too little time, will be ignored by the immune system. This model, when
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applied to transplant antigens, implies that variation in the quantity or functional
availability of tissue that facilitates interaction between antigen presenting cells and
immunoreactive lymphocytes is a significant variable in determining the likelihood of
reactivity. Precise understanding of the exact location of this immunological interaction is
therefore of crucial importance if one is to successfully develop techniques to prevent the
loss of ignorance, thereby facilitating the long-term survival of allografts.

The location of the alloimmune response
Preserving immunologic ignorance by interrupting the communication lines between the
various parts of the adaptive immune response requires knowledge of where these
interactions take place within the immune system. Most research to date has focused on
the transport of antigen to secondary lymphoid tissue.
In 1968, Barker and Billingham demonstrated that skin grafts were rejected much more
quickly when implanted into a recipient site that allowed lymphatic outflow, compared to
placement in a vascular bed without lymphatic drainage (2). The presumptive mechanism
behind this phenomenon is that secondary lymphoid tissue provides a permissive context
for direct recognition of alloantigens that are presented by graft-derived antigen presenting
cells to naïve T lymphocytes, which reside in these peripheral lymph nodes. Activated T
lymphocytes then respond swiftly against graft tissue.
Consistent with this model, it was demonstrated in 2000 that a mouse devoid of secondary
lymphoid tissue would indefinitely accept a vascularized allograft (3).

Because the

lymphocytes from these mice were able to mount an effective response if transferred to
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another animal with intact lymphoid organs, it was concluded that the inability to reject
the allograft in the lymphoid-deficient animal was due to immunologic ignorance,
maintained by the inability of antigen presenting cells and potentially reactive lymphocytes
to interact. This suggests that secondary lymphoid tissue is essential for the interaction
between antigen-presenting cells and reactive antigen-specific lymphocytes.

Tertiary Lymphoid Tissue
There remains an additional possible lymphoid site for the activation of alloreactive
lymphocytes.

In addition to the embryonically derived lymphatic system, mucosal

lymphoid tissue and the spleen (together, the traditional secondary lymphoid tissue) there is
evidence that ectopic lymphoid tissue located in the peripheral tissues, known as tertiary
lymphoid tissue, is able to contribute to the development of an immune response against a
wide array of antigens.
Tertiary lymphoid organs (TLO) are organized collections of T cells, B cells and antigen
presenting cells that form in peripheral tissue, usually in association with chronic
inflammation.

This ectopic lymphoid tissue displays a wide range of anatomical

organization, ranging from simple expression of lymphoid-related signaling molecules to
full-fledged lymph node-like structures with characteristic high endothelial venules,
germinal centers, and specific areas of B- and T cell localization.

Distribution of Tertiary Lymphoid Tissue
TLO have previously been shown to be present in multiple pathologic conditions, including
autoimmunity, infection and neoplasia.
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Tertiary lymphoid organs in autoimmune disease
TLO have been observed at the site of autoimmune processes such as Sjögren’s disease,
Graves’ and Hashimoto’s thyroiditis, and rheumatoid arthritis (4). Thyroid tissue from
patients with both Graves’ and Hashimoto’s disease has been noted to display lymphoid
accumulations with high grade architecture, including high endothelial venules near
organized T cell areas, distinct B cell follicles, and plasma cell concentrations (5). These
lymphoid follicles contain high levels of antibodies specific for thyroid antigens and are
sites of high levels of recombinase gene expression (RAG1, RAG2), suggesting that
affinity maturation of lymphocytes against thyroid antigen occurs within these TLO (6).
The localization of leukocyte subsets within the circulation and the tissues is determined by
the differential expression of chemokines, integrins, and other adhesion and
communication molecules, which enable lymphocytes to enter or leave specific tissues.
Analysis of chemokine expression can provide an indication that a particular tissue is
actively engaged in the recruitment of a particular type of leukocyte. The chronically
inflamed joint in rheumatoid arthritis has been demonstrated to display elevated levels of B
and T cell homing chemokines, such as CXCL13, CXCL12 and CCL19, constitutively,
which suggests a mechanism for the organization of ectopic lymphoid tissue near the site of
pathology (7).

Synovial tissue in rheumatoid arthritis displays lymphoid-like

accumulations of CD4 T cells within the inflamed synovial membrane. These collections
have been demonstrated to be functional, as the germinal center-like structures in the
synovial tissue support hypermutation and terminal B cell differentiation (8).
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Similar structures have been found in Sjögren’s syndrome, an autoimmune disease
characterized by autoantibody assault on salivary gland tissue.

As in the case of

rheumatoid arthritis, ectopic expression of T and B cell chemokines (CXCL12 and
CXCL13 respectively) and formation of germinal center-like structures has been noted
within affected salivary tissue (9). It has been further demonstrated that these germinal
centers produce characteristic Anti-Ro and Anti-La autoantibodies, suggesting that local
antibody production contributes to the pathology of the disease (10).

Tertiary lymphoid organs in infection and neoplasia
TLO have been noted in multiple organs during infectious challenge. In response to
infection or inflammation, it has been shown that germinal center-like tissue appears in the
lungs of infected mice (11).

This lymphoid tissue is known as inducible bronchus-

associated lymphoid tissue, or iBALT. This tissue expresses the lymphoid chemokines
BLC (CXCL13) and SLC (CCL21), and on histologic examination, distinct T- and B cell
areas are found within iBALT. In transgenic mice that lack other components of the
peripheral lymphoid system (lymph nodes, spleen, Peyer’s patches), iBALT has been
shown to be sufficient to mount a functional immune response against viral infection,
showing that TLO can fully support immune reactions without depending on native
secondary lymphoid organs.
There have been multiple findings of TLO in the context of bacterial infection. Liverspecific peripheral immune tissue has been noted during hepatic granulomatous infection
with Propionibacterium actes (12). TLO in murine small intestine are functional sites for
the production of antigen specific IgA following bacterial challenge (13). Vessels with
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histologic and biochemical similarity to lymphoid tissue have been described in gastric
mucosa in correlation with Helicobacter pylori infection, and were noted to recede with
antibiotic eradication of the microbe (14).
In invasive ductal carcinoma of the breast, ectopic germinal centers in intratumoral follicles
support affinity maturation of B cells, with enhanced reactivity of follicular antibodies
toward tumor antigens, suggesting a beneficial autoimmune response generated within
TLO against malignant tissue (15).

Development of Lymphoid tissue
Lymphoid neogenesis occurring in peripheral tissue is believed to recapitulate the
development of lymphoid tissue that takes place during organogenesis (16). Because of the
parallels between fetal lymphogenesis and ectopic lymphoid neogenesis, and the
importance of the transgenic models with germ-line defects in lymphogeneic pathways, the
development of lymph nodes during embryogenesis will be briefly reviewed.

Fetal lymphogenesis
In the developing fetus, lymphogenesis occurs early in organogenesis, soon after the
development of the vasculature. In murine development, this occurs on embryonic day 11
when buds of endothelial cells begin to project off venous conduits, near sites of signaling
molecules.
Development of lymph nodes critically depends on interaction between hematopoietic
“inducer” cells and stromal cells, which display both the adhesion molecule VCAM1 and
the lymphotoxin-β receptor (LTβR). Both of these cells are present in early lymph node
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anlagen. The inducer cells bear both the LTβR ligand LTα1β2 and the integrin α4β1 that is
able to bind to the VCAM1 adhesion molecule on stromal cells described above. Once
bound to VCAM1, LTα1β2 mediated signaling of the LTβR on the stromal cell can take
place.
T H E L Y M P H O T O X I N -B E T A R E CE P T O R
Signaling through the lymphotoxin-β receptor is critical to the formation of lymph nodes,
and can be accomplished by two members of the TNF-family, the ligands LTα1β2 and
LIGHT. Because LIGHT deficient mice do develop lymphoid tissue, it is presumed that
LTα1β2 plays a dominant role. Mice deficient in lymphotoxin alpha(LTα) do not develop
lymph nodes or Peyer’s patches (17)(18). In such mice, treatment of pregnant mice with
agonist antibody that is capable of stimulating the LTβR will restore lymph node
development in offspring, thus demonstrating the critical role of LTβR in the development
of lymph nodes (19) Blockade of the LTβR in utero with soluble blocking antibody will
prevent the formation of most lymph nodes; however, a subset of mucosal lymph nodes
will still develop, indicating that the LTβR pathway is not the exclusive trigger for
lymphogenesis (20).
The LTβR mediates signaling through two distinct NFκB related pathways (21). These
pathways are relevant to this experiment because an important murine model of ignorance,
the aly/aly mouse, involves a mutation in a component of these pathways. In the initial
“classical” LTβR receptor signaling pathway, LTβR ligation induces activation of an IKK
complex, initiating a signaling pathway that results in upregulation of adhesion molecules
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ICAM1, VCAM1 and MAdCAM-1 (22). The increased synthesis of these adhesion
molecules may lead to further inducer cell adherence, thereby exponentially increasing
LTβR signaling through positive feedback from the increased population of inducer cells.
The second “alternative” LTβR signaling pathway leads to NFκB-inducing kinase (NIK)
activation, which triggers IKKα and subsequently induces upregulation of transcription of
multiple chemokines that are critical for lymphoid cell homeostasis including SLC
(CCL21), BLC (CXCL13), and ELC (CCL19) (23). The aly/aly mouse is the result of a
point mutation in the NIK gene, which prevents activation of the alternative LTβR
pathway. Because of this inhibition, the aly/aly mouse possesses neither lymph nodes nor
Peyer’s patches, in addition to other defects including the absence of mammary glands, and
abnormal splenic and thymic architecture (24).
During the development of lymph nodes, other critical signaling molecules are expressed,
including the addressins PNAd (peripheral node addressin) and MAdCAM-1(mucosal
addressin cell adhesion molecule), as well as enzymes such as HEC-6ST, which is
necessary to appropriately sulfate these glycoproteins (25).

The presence of these

molecules has proved useful for the identification and localization of ectopic lymphoid
tissues.

Experimentally induced lymphoid neogenesis
Mice that transgenically express ligands of the LTβR or the TNF receptor (TNFR) will
develop inflammatory lesions at the site of expression (16). Such lesions have been shown
to display characteristics of organized lymphoid tissue. RIP-LTα transgenic mice, which
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express lymphotoxin-α under the control of the rat insulin promoter, develop chronic
inflammatory lesions in the skin, pancreas and kidney. Pancreatic and renal lesions have
been shown to contain T and B lymphocytes, plasma cells, and antigen presenting cells,
and are the site of expression of lymphoid homing chemokines such as secondary lymphoid
chemokine (SLC) and B lymphocyte chemokine (BLC) (26).

The lesions display

anatomically delineated areas with resident cells arranged in a manner similar to a classic
lymph node. Formation of these lesions is critically dependent on the presence of TNF
receptor 1 (27). Skin lesions in RIP-LTα transgenic mice appear histologically similar to
the pancreatic and renal lesions, however there remains a need for further characterization
of the contents of intradermal lesions. Mice with transgenic expression of both LTα and
LTβ show accumulations with even more distinct T and B cell compartmentalization and
prominent follicular dendritic cell networks within ectopic lymphoid tissue (25).
Furthermore, expression of characteristic lymph node molecules such as PNAd and HEC6ST as well as lymphoid chemokines can be observed within the lesions.

Tertiary lymphoid organs and the alloimmune response
To date, the functional capacity of TLO in allograft rejection has not been conclusively
demonstrated. It has previously been shown that an immune response to an allogeneic
vascularized transplant is dependent on the presence of secondary lymphoid organs (3).
This paper demonstrated that in a splenectomized aly/aly model, devoid of all secondary
lymphoid tissue, vascularized cardiac allografts were accepted indefinitely. It was shown
that despite the failure to reject the allograft, the host immune cells remained competent,
and were able to mediate rejection either if lymphocytes were transferred to recipients with
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intact lymphoid structures or if exogenously activated T cells were transferred to
transplant recipients. Because the acceptance of the grafts occurred without
immunosuppression, and coexisted with an otherwise functional immune system,
immunologic ignorance of the allograft was presumably a consequence of the absence of
secondary lymphoid tissue.
Lymph node-related adhesion molecules have been noted to be present at the sites of
allograft rejection. In a study of human post-transplant endomyocardial biopsy samples,
Toppila et al. demonstrate an increased level of expression of L-selectin ligands selectively
during the acute rejection episodes (28).

This ligand, which mediates lymphocyte

extravasation into peripheral tissue, was not present in the absence of rejection, and the
magnitude of its expression was correlated with the degree of rejection. Kirveskari, et al,
similarly demonstrate the upregulation of L-selectin ligands on kidney endothelial tissue
solely during episodes of acute rejection, also with a magnitude of expression correlated
with the degree of rejection (29). The presence of this lymphocyte ligand suggests a
mechanism for the incursion of lymphocytes into graft tissue, thereby facilitating rejection.
The possibility that there is an additional site of interaction between APCs and naïve T
cells during graft rejection follows from the identification of organized lymphoid structures
within murine cardiac allografts undergoing chronic rejection (30).

In this study,

lymphoneogenesis was invariably associated with rejection: all recipients with either
tertiary lymphoid organs with discrete T and B cell zones and PNAd positive high
endothelial venules(HEV), or only less organized PNAd+ HEV, were found to have some
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degree of rejection. Of the allografts with chronic rejection, 78% had identifiable
lymphoid neogenesis. Allografts or syngeneic grafts that were not undergoing rejection did
not have evidence of lymphoid neogenesis.
Recently, similar findings were found in human cardiac and kidney tissues that were
explanted following chronic rejection. In all rejected organs, but not in control explants,
germinal center-like structures were found that contained T lymphocytes and areas of
proliferating B cells in close proximity to follicular dendritic cells (31). In a rodent
transplant model by the same authors, areas of TLO found in the vascular endothelium of
transplanted aortic tissue displayed HEV phenotypic markers and organized lymphoid
anatomy. The cell population within the TLO changed over time from a CD8 T cell
infiltrate consistent with an acute cytotoxic response to a CD4 T cell population that
displayed cell surface markers characteristic of helper T cells that assist resident B cells.
This close linkage between allograft rejection and the presence of ectopic lymphoid tissue
suggests that there is a functional role for tertiary lymphoid tissue in the alloimmune
response.

The current study creates an experimental model to prospectively test the

relationship between ectopic lymphoid tissue and transplant rejection.
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STATEMENT OF PURPOSE, SPECIFIC HYPOTHESIS
AND SPECIFIC AIMS OF THE THESIS

The review above suggests that ectopic lymphoid tissue may play a role in the loss of
immunologic ignorance of an allograft, and thus may be a site of interaction between
antigen presenting cells and T cells that is critical for allograft rejection. Demonstrating
that the presence of ectopic lymphoid tissue is associated with graft rejection, the absence
of ectopic lymphoid tissue is associated with immunologic ignorance, and the transfer of
ectopic lymphoid tissue can reconstitute an alloimmune response would, in a manner
consistent with Koch’s postulates, strongly suggest a functional role for ectopic lymphoid
tissue in the rejection of tissue allografts. Understanding the capacity of specific tissue to
play a contributory role in allograft rejection may prove significant in developing therapies
designed to prevent rejection of transplanted organs and tissue.
The specific hypothesis of this thesis is that ectopic lymphoid tissue in transplanted skin
acts as functional lymphoid tissue and is sufficient to break immunologic ignorance. This
thesis aims to prove this hypothesis by demonstrating the loss of immunologic ignorance
and the development of specific lymph node function following the introduction of
intragraft TLO into a transplant model, and by assessing the growth and transformation of
T cells in mice with transplants containing tertiary lymphoid tissue.
To explore the functional capacity of tertiary lymphoid organs in supporting the
alloimmune response and the breakage of immunological ignorance, we compare here the
survival of wildtype allogeneic skin grafts (allografts), syngeneic RIP-LTα skin grafts that
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have ectopic lymphoid tissue transgenically expressed in the skin, and allogeneic RIPLTα skin grafts, also with dermal ectopic lymphoid tissue, after transplantation to
splenectomized aly/aly (aly/aly-spleen) mice without secondary lymphoid organs (figure
1).

Donor

Graft

WT

WT

F1

LTα

B6
LTα
F1

allo

Recipient

aly/aly

B6

LTα

aly/aly

syn

B6

LTα

allo

aly/aly

B6

Figure 1 The experimental groups. Donor tissue is either
allogeneic wild-type, syngeneic LTα transgenic or allogeneic
LTα transgenic skin. All recipients are splenectomized aly/aly B6
mice.

It is expected that splenectomized aly/aly mice will remain ignorant of an allograft,
consistent with prior published research. It is the first aim of this thesis to test whether the
presence of ectopic lymphoid tissue in an allograft will be sufficient to break immunologic
ignorance in this host and will lead to rejection of allografts that would otherwise remain
accepted. Control syngeneic transplants, with or without intragraft TLO, should show no
rejection.
If ectopic lymphoid organs actually function as lymph nodes, then it should be
demonstrable that the presence of this tissue permits the development of the effector and
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memory components of an allograft rejection response. The second aim of this thesis is
to assess the response of a splenectomized aly/aly mouse to an allogeneic skin graft
following simultaneous transplantation of allogeneic RIP-LTα skin, prior transplantation of
allogeneic RIP-LTα skin, or prior transplantation of syngeneic RIP-LTα skin.

As

mentioned above, the splenectomized aly/aly mouse has been shown to accept allografts
indefinitely, without developing an effector or memory response. If tertiary lymphoid
tissue present in the RIP-LTα skin does indeed function as a lymph node, then one would
expect to observe the establishment of an allospecific effector T cell response at the time of
RIP-LTα skin transplant and generation of memory T cells, which are able to mediate the
rejection of subsequent transplants.
The third aim of this thesis is to assess and quantify the actual development of T cells with
effector and memory phenotypes in otherwise lymphoid-organ free mice that receive a
transplant of allogeneic TLO-containing skin. If the hypothesis is true, then one should be
able to transfer congenic naïve lymphocytes to aly/aly mice, and, following an allogeneic
TLO-containing transplant, reharvest the same lymphocytes and observe an increase in
expression of markers of effector and memory phenotypes on these cells.
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METHODS

Mice: Wildtype (wt) C57BL/6 (B6, Thy1.2, H-2b), B6.PL-Thy1a/Cy (B6.1.1, Thy1.1, H2b), and CB6F1/J (H-2d/b) mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). alymphoplasia (aly/aly) mice (Map3k14-/-, Thy1.2, H-2b), were purchased from
CLEA Japan (Osaka, Japan) and bred under specific pathogen free conditions. A RIP-LTα
mouse colony (B6, Thy1.2, H-2b) was originally obtained from Nancy Ruddle (Yale
University) and maintained at the Yale Animal Resource Center. RIP-LTα (B6, Thy1.2,
H-2b) were crossed with BALB/cJ (Thy1.2, H-2d) to generate RIP-LTα F1(CB6F1/J, H2b/d) mice.

Surgical Procedures:
S P L E N E CT O M Y :
Splenectomy was performed under general anesthesia via a subcostal incision at least 1
week prior to transplant procedure. Completeness of splenectomy was verified postmortem in every mouse.
SKIN TRANSPLANTATION:
Full thickness skin transplantation was performed as follows.

The transplant was

performed using general anesthesia. Abdominal skin, free of nevi or scarring, from donor
mice was harvested and subcutaneous layers removed by gentle scraping underneath a cold
saline bath. Recipient mice were 8-12 week old B6 aly/aly splenectomized mice. A 1.53.0 cm2 graft bed was prepared on the dorsal flank of the recipient by excision of native
skin. Donor skin was trimmed to fit the prepared bed, placed in situ and secured with skin
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staples and bandages for seven days. Mice received acetaminophen in their drinking
water for 3 days postoperatively for analgesia. Graft viability was monitored daily for the
first seven days, after which grafts were monitored every other day. Rejection was defined
as > 90% graft necrosis. Acceptance was defined as complete healing of the graft with
evidence of hair growth.

Lymphocyte isolation and characterization
ISOLATION AND ADOPTIVE TRANSFER OF NAÏVE T CELLS:
Spleen and lymph node cells were harvested from Thy1.1+ B6 mice to obtain naïve T cells.
Harvested cells were enriched for T cells using Nylon Wool Fiber Columns (Polysciences,
Inc., Warrington, PA). Nylon wool purified T cells were then labeled with fluorochrome
tagged antibodies against CD4, CD8 and CD44.

These cells were sorted for naive

CD4+CD44lo and CD8+CD44lo populations (> 98% purity) using a FACS Aria high-speed
cell sorter.
Sorted naive CD4 or CD8 T cells (Thy1.1, H-2b) were injected intravenously into the tail
vein of splenectomized aly/aly (aly/aly-spleen, Thy1.2, H-2b) recipients three days
following skin transplantation. Adoptive hosts received 5 x 106 sorted cells.
CELL HARVEST AFTER ADOPTIVE TRANSFER:
Mice were perfused with heparin (100 U/ml) at the time of sacrifice. Blood was removed
by cardiac puncture and erythrocytes were lysed with pure water. The liver was perfused
via the portal vein with 50 U/ml collagenase IV solution (Worthington Biochemical,
Lakewood, NJ), removed and passed through a 70 µm strainer. The tissue suspension was
incubated at 37ºC with 50 U/ml collagenase IV in RPMI 1640 plus 5% FCS for 30
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minutes. Lymphocytes were then separated on a 25% Optiprep gradient (Accurate
Chemical and Scientific Corp., Westbury, NY). Lungs were perfused with PBS via right
ventricular cannulation, removed, finely macerated and incubated at 37ºC in 50 U/ml
collagenase IV solution for 60 minutes. The digested tissue was passed through a 100µm
strainer followed by centrifugation and RBC lysis. To obtain bone marrow cells, the femur
and tibia were flushed with PBS and the cell suspension was centrifuged followed by RBC
lysis. The skin was harvested, minced and digested at 37ºC for 2 hours in a solution
containing 2.7mg/ml collagenase, 1mg/ml DNAse, 0.25mg/ml hyaluronidase.

The

digested tissue was passed through a 100µm strainer.
FLOW CYTOMETRY STAINING:
Flow cytometry was performed to phenotype naïve, effector and memory lymphocytes and
to isolate congenic (Thy1.1+) lymphocytes prior to and following adoptive transfer.
Fluorochrome-conjugated antibodies were purchased from BD Pharmingen (San Diego,
CA), eBioscience (San Diego, CA) or SouthernBiotech, (Birmingham, AL). Antibodies
were against CD4 (RM4-5), CD8a (53-6.7), CD44 (Pgp-1), CD62L (MEL-14), and
CD90.1 (OX-7) moieties. Flow cytometry was performed was done on FACS Aria or
LSRII analyzers (BD Biosciences). Data were analyzed using FlowJo software (Tree Star,
Inc., Ashland, OR).
I N V I V O P RO L I F E R A T I O N A S S A Y
Sorted Thy1.1+ CD4 and CD8 effector or memory T cells were labeled with CFSE
(Molecular Probes, Eugene, OR) for 10 minutes at 37ºC, washed and adoptively transferred
to either aly/aly-spleen or wt recipients (Thy1.2). Lymphocytes were harvested 15 or 60
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days later from lymphoid and non-lymphoid tissues according to the protocol described
above. Thy1.1+ lymphocytes were isolated by flow cytometry and the extent of cell
proliferation was measured by CFSE dilution in the transferred cell population.

Delineation of work
The design and implementation of this research depended greatly on a team with diverse
strengths, talents and experience.

Preliminary research and alternative experimental

strategies were investigated by Fadi Lakkis, Zenhua Dai, Michael Reel and Isam Nasr.
Experimental methodology was designed by Fadi Lakkis, Isam Nasr and Michael Reel.
Murine surgery was performed by Isam Nasr and Michael Reel. Graft survival was
monitored by Isam Nasr.

Isam Nasr and Michael Reel accomplished lymphocyte

harvesting, with technical assistance provided by Lakkis Lab members. Flow cytometry
was performed primarily by Martin Oberbarnscheidt. Statistical analysis was performed by
Isam Nasr and Michael Reel. Preparation of figures to incorporate graphic elements
constructed by Isam Nasr.
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RESULTS

Finding 1: Tertiary Lymphoid Organs are associated
with graft rejection
It has previously been demonstrated that a splenectomized aly/aly mouse will indefinitely
accept a vascularized allograft (3), where it was found that the acceptance was due to
immunologic ignorance of the graft. To explore the hypothesis that tertiary lymphoid
tissue is sufficient to break such immunologic ignorance, it is necessary to show that in an
otherwise ignorant model, the singular addition of tertiary lymphoid tissue leads to
rejection. In order to demonstrate this, skin transplants from transgenic RIP-LTα mice
were grafted onto aly/aly splenectomized mice. RIP-LTα mice express lymphotoxin-α
under control of the rat insulin promoter, and display markedly increased expression of
LTα in the pancreas, skin and the kidney. The expression of LTα in these areas leads to
the local development of ectopic lymphoid tissue, similar in nature to that found in a lymph
node, and notably similar to the tertiary lymphoid tissue found at the sites of allograft
rejection in wild-type animals receiving vascularized allografts. Transplant of allogeneic
RIP-LTα skin accomplishes both the establishment of ectopic lymphoid tissue as well as
the implantation of antigenic tissue. Transplantation of syngeneic LTα-expressing donor
skin is used to control for inflammatory stimuli occurring as a consequence of either the
surgical transplant procedure or the expression of LTα.
Three different experimental skin transplant conditions were examined. In all cases, skin
transplant recipients were splenectomized aly/aly B6 mice. In case 1, the donor mouse was
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a wild-type F1 generation BALB/c x B6 mouse, allogeneic to the B6 recipient.
Consistent with previously reported research(3), all six aly/aly recipients indefinitely
accepted allogeneic skin transplants. In case 2, the donor was a syngeneic B6 RIP-LTα
transgenic mouse, which expressed LTα in the skin, including skin used for transplant.
This syngeneic transplant was also accepted indefinitely (n = 6). Case 3 incorporated an
allogeneic, F1 generation BALB/c x B6 transgenic RIP-LTα mouse as the donor. When
skin from this donor, which contains tertiary lymphoid organs, was transplanted onto a B6
aly/aly recipient, the skin was rejected in a median of 18 days (n = 12) (figure 2).
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Figure 2 Differential survival of allografts containing tertiary
lymphoid organs. Allogeneic wild-type skin and syngeneic LTαexpressing skin transplants are accepted indefinitely (n=6).
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Finding 2: Tertiary Lymphoid Organs can function
as a lymph node, and can enable effector and
memory allograft rejection responses
The alloimmune response occurs in two phases.

At the time of a transplant, naïve

allospecific T cells that encounter antigen presenting cells bearing alloantigen receive
costimulatory signals and become activated T cells. Clonal expansion of these activated T
cells occurs, developing an effector response that may lead to the rejection of the allograft.
Following the effector response, there is a dramatic contraction of reactive lymphocytes,
during which the vast majority of the expanded reactive cell population undergo apoptosis.
At the conclusion of this process, a select number of reactive cells remain in the circulation
as memory T cells, which are able to mount a swift response in the periphery if antigen is
encountered at a later time.
In the context of immunologic ignorance, however, neither the effector, nor memory
response occurs, leading to acceptance of alloreactive tissue. One such cause of ignorance
is a failure of antigen presenting cells to present antigen to naïve alloreactive lymphocytes.
It is theorized that the immunologic ignorance of a splenectomized aly/aly mouse is a
consequence of the lack of secondary lymphoid tissue, leading to a failure of interaction
between antigen presenting cells and T lymphocytes. If this hypothesis is true, then
transplanting tissue containing ectopic lymphoid tissue should be presumed to supply such
a meeting site, and should be expected to permit rejection of allogeneic tissue.
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To examine the ability of ectopic lymphoid tissue to permit an effector alloimmune
response, a recipient splenectomized aly/aly mouse simultaneously receives two skin
transplants.

One graft comes from a wild-type F1 BALB/c x B6 mouse, which is

allogeneic to the B6 aly/aly. As mentioned above, as a stand-alone transplant, this graft
would normally be accepted indefinitely. The second graft, placed on the opposite flank of
the recipient in the same surgical procedure, comes from an allogeneic F1 BALB/c x B6
RIP-LTα transgenic mouse. When this operation was performed on six recipients, both
grafts were rejected in all animals. The median graft survival time was 52 days for the wt
graft and 53 days for the F1 RIP-LTα graft (figure 3). Thus, the presence of a LTα
expressing allograft precipitated the rejection of an otherwise ignored allograft.
Surprisingly, the time to rejection was considerably longer when simultaneous transplants
were performed (figure 3) than when a single transgenic transplant was performed (figure
2). Reasons for this delay in rejection are unclear, but may possibly be related to the
aggregate quantity of grafted tissue that is rejected.
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Figure 3 TLO permit generation of effector T cells. When LTα
skin and wt allogeneic skin are simultaneously transplanted, the
LTα skin allows the rejection of both grafts

To examine the ability of tertiary lymphoid tissue to spur a memory alloimmune response,
6 aly/aly recipients were given asynchronous allogeneic skin transplants.

Initially,

allogeneic grafts from F1 BALB/c x B6 RIP-LTα mice were placed, with rejection
occurring shortly after (MST 21 days), consistent with the first experimental finding
described above (figure 4). 50 days later, after the graft tissue had necrosed and been
replaced by scar, a second transplant was performed, using wild-type allogeneic F1
BALB/c x B6 skin. Despite the lack of secondary or tertiary lymphoid tissue in this twicetransplanted aly/aly recipient, the second graft was also rejected, with a median survival
time of 17 days, thus suggesting that antigen specific memory T cells that had been
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generated during the initial transplant were still circulating and retained the functional
capacity to reject subsequent allograft tissue.
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Figure 4 TLO permit generation of memory T cells. When
allogeneic LTα skin is transplanted and allowed to reject,
subsequent wt allogeneic grafts are rejected, rather than accepted
as in Fig. 2.

In the final demonstration of the functional capacity of ectopic lymphoid tissue, six
splenectomized aly/aly recipient mice again receive two asynchronous transplants. In this
case, the initial transplant comes from a syngeneic B6 RIP-LTα donor. As in the control
for the first experiment (figure 2), the syngeneic transplant is accepted, demonstrating again
that RIP-LTα does not independently trigger graft rejection (figure 5). With an accepted
syngeneic skin graft remaining in place, the animal receives a second, wild-type allogeneic
F1 BALB/c x B6 skin graft on the opposite flank. The initial graft remains undisturbed. In
this case, the new wild-type allograft is no longer accepted by the aly/aly recipient, but is
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instead rejected in a median of 31 days, suggesting a functional role for the ectopic
lymphoid tissue located in the syngeneic graft on the contralateral flank of the recipient.
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The preceding findings demonstrate on a macroscopic scale the tolerance-breaking effects
of tertiary lymphoid organs in transplantation and demonstrate a tight correlation between
the presence of ectopic lymphoid tissue and the rejection of an allograft. The third
component to this thesis demonstrates on a cellular scale the change in the phenotype of T
lymphocytes that occurs as a result of the presence of tertiary lymphoid organs.
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If tertiary lymphoid organs act as lymph nodes then they must be able to permit the
activation of naive lymphocytes and the development of T cells with effector and memory
phenotypes. To assess whether tertiary lymphoid tissue could activate lymphocytes, naive
T lymphocytes (CD44low) were harvested from Thy1.1+ mice. These lymphocytes are
otherwise identical to lymphocytes from Thy1.2+ wild-type mice, but can be specifically
identified by the Thy1.1 antigen expressed on T cells. Experimental subjects were
splenectomized aly/aly B6 mice that had three days previously received a skin transplant
from an allogeneic F1 BALB/c x B6 RIP-LTα expressing mouse. Control animals were
aly/aly splenectomized B6 mice that received allogeneic BALB/c x B6 wild-type skin or
syngeneic B6 RIP-LTα skin. In each lymphocyte transfer, 5 million Thy 1.1+ lymphocytes
were injected into the tail vein of the recipient mouse.
Recipients were divided into two groups based on the timing of the lymphocyte harvest.
Lymphocytes from the first group were harvested at 15 days post-transfer in order to assess
the development of effector T lymphocytes. Lymphocytes from the second group were
harvested at 60 days, at which point the effector response would have been concluded, and
lymphocyte levels returned to baseline, leaving only memory antigen-specific T
lymphocytes.
At each harvest date, lymphocytes were retrieved from skin, lung, liver, bone marrow, and
peripheral blood. Thy 1.1+ CD4 and CD8 T lymphocytes were isolated via flow cytometry,
and the population was stratified based on expression of CD44 and CD62L, markers of T

lymphocyte activation.
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Lymphocytes were recoverable in small but identifiable

quantities from all locations.
In experimental animals transplanted with allogeneic RIP-LTα skin, when harvested at the
15 day time point, Thy 1.1+ lymphocytes displayed an increase in expression of CD44, a
decrease in CD62L expression, and significant dilution of intracellular CFSE, consistent
with expansion of the Thy 1.1+ cell population and transformation from a naïve to an
effector phenotype (figure 6). Control animals were transplanted with syngeneic RIP-LTα
grafts. Thy 1.1+ lymphocytes were recovered in only very minimal quantity. CFSE
staining did not reflect rounds of cell division, and CD62L or CD44 expression did not
demonstrate transformation of the naïve transferred cells into effector or memory
lymphocyte phenotypes. Thy 1.1+ lymphocytes were not recoverable from recipients of
wild-type non-transgenic grafts, despite identical harvest techniques, suggesting that the
absence of lymphoid tissue failed to permit survival or expansion of the transferred
lymphocytes
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When harvested at the 60 day time point, transferred Thy 1.1 lymphocytes harvested
+

from liver specimens demonstrate an increase in expression of both CD62L and CD44,
consistent with a transformation from a naïve phenotype to a central memory phenotype
(figure 7). There is a single CD62L peak, consistent with the apoptotic elimination of the
effector phenotype seen at the 15 day harvest point.
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DISCUSSION

This study demonstrates that rejection of an allograft in a mouse devoid of secondary
lymphoid tissue occurs if there is simultaneous transplantation of ectopic lymphoid tissue
as well as alloantigen. Immunogenic effects of inflammation related to the simple presence
of the RIP-LTα transgene were controlled for by the inclusion of syngeneic transplants.
These syngeneic grafts were not rejected, although they contained TLO. Thus, differential
graft survival in mice that receive allogeneic transplants from RIP-LTα donors must be a
function of the additional TLO.
We further characterized the functionality of this TLO by analyzing the differential ability
of the tissue to support the development of effector and memory adaptive immune
responses. When present, TLO were sufficient to endow a previously immunologically
quiescent mouse with an operational rejection response, demonstrating the presence of
effector T lymphocytes.

Ectopic TLO also supported a delayed rejection capacity,

consistent with the development of memory T cells. Lastly, we found that TLO provided
an aly/aly mouse with a newfound ability to reject anatomically distant foreign tissue,
demonstrating the ability of the ectopic tissue to support a systemic immune response.
These functional correlations were explored on the cellular level by the identification and
quantitation of specific T lymphocytes with phenotypes characteristic of effector and
memory T cells. CD62L is a selectin that facilitates, and is required for, lymphocyte
entrance into in lymph nodes, by binding glycoproteins such as GlyCAM-1 or MAdCAM-1
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on the endothelium of lymph node high endothelial venules. These glycoproteins are
collectively referred to as peripheral node addressins (PNAd). CD62L is expressed on
naïve lymphocytes, enabling their entry into lymph nodes to survey incoming APCs for
activating antigen. If a T cell becomes activated, CD62L is downregulated, enabling egress
from the lymph node into the circulation, for eventual traffic into a target organ where
effector activity may take place. CD44 is another differential marker of activated T cells.
The transition from CD62Lhigh to CD62Llow and from CD44- to CD44+ observed here in
mice receiving LTα expressing transplants is consistent with a loss of naïve phenotype for
the transferred Thy1.1+ lymphocytes. The dilution of CFSE is consistent with successive
rounds of cellular division occurring in this cell population. Both of these events occurred
only in those mice that received ectopic TLO, suggesting that the transplanted TLO was
capable of providing a location in which this transformation could take place.
Our experiments confirm that TLO are sufficient to break immunologic ignorance, and
demonstrate macroscopic and microscopic evidence of lymphocyte activation, allograft
rejection and the formation of immunologic memory in the presence of TLO. These results
are consistent with prior research that demonstrated an inability of mice devoid of
secondary lymphoid tissue to reject allogeneic grafts (3). Interpretation of this prior
research had been made more complicated following reports by other groups who found
that in different models of mice without secondary lymphoid tissue, lymphotoxin-α or
LTβR knockout mice, rejection of cardiac and skin tissue was delayed, rather than
abrogated (32). Differences in the specific model used for as the lymphoid tissue-deficient
model have been suggested to underlie the different conclusions of the two groups
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regarding the necessity of secondary lymphoid tissue for an allograft response.
Lymphocytes from aly/aly mice have previously been reported to display defects in homing
to gastric-associated lymphoid tissue (33), suggesting that perhaps aly/aly lymphocytes
have an inherently poor ability to enter ectopic lymphoid tissue. However, the results
described herein suggest that the small amount of ectopic lymphoid tissue accompanying
the allograft is traversable by recipient lymphocytes, as its presence correlates with
rejection and the development of effector and memory lymphocyte phenotypes.
Alternative explanations for the differential rejection behavior following transplant of RIPLTα ectopic lymphoid tissue are constrained by the failure of the control syngeneic RIPLTα tissue to be rejected, and its ability to support rejection of foreign tissue. If there
existed a factor inherent to RIP-LTα expression that is capable of inducing extralymphatic
activation of recipient lymphocytes, then one would expect this factor to have induced
rejection following a syngeneic RIP-LTα transplant. The absence of such syngeneic
rejection supports the determination that it is the presence of the lymphoid tissue itself that
endows the ability to reject allogeneic tissue.
Prior research has not specifically characterized the cellular components of the skin lesions
found in RIP-LTα transgenic mice.

While these lesions appear to have histological

characteristics of lymphoid tissue, and are the sites of expression of lymphoid
glycoproteins such as PNAd (unpublished data), in vivo demonstration of the lymphoid
functionality of these accumulations has not been previously published. The evidence
presented herein constitutes a functional demonstration of the lymph node-like abilities of
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RIP-LTα skin. When transgenic RIP-LTα skin, containing the characteristic lymphoid
structures, is transplanted, it empirically performs as a lymph node, which is consistent
with its classification as functional tertiary lymphoid tissue.
Our results are consistent with prior research that has demonstrated that lymphoid tissue is
found near the site of allografts undergoing rejection. Within the framework of
Zinkernagel’s localization-dose-time model of immunologic function, the formation of
ectopic lymphoid tissue could be considered an additional mechanism for fostering the
interaction between lymphoid-resident cells and APCs. Establishment of lymphoid tissue
close to the site of antigen complements the more commonly appreciated traffic of antigen
toward lymphoid tissue. The placement of lymphoid tissue close to the site of an allograft
enhances the likelihood of an immunologic response, thereby leading to observed increased
frequency of rejection when this tissue is present. This is also consistent with the presence
of tertiary lymphoid tissue in close proximity to autoimmune activity. When lymphoid
tissue is brought closer to antigens that normally would not be recognized by the immune
system, ignorance is more likely to be broken, facilitating autoimmune response against
normally non-immunogenic self targets.
Combined with knowledge of the pathways leading to lymphoid tissue development, these
findings suggest therapeutic benefit from interventions designed to enhance or inhibit the
development of tertiary lymphoid organs, in an effort to augment or suppress interaction of
antigen-presentation to reactive lymphocytes. If local ectopic lymphoid tissue facilitates
the development of autoimmune pathology, then interruption of lymphoid signaling
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pathways underlying the growth and organization of ectopic tissue may be expected to
lead to reduction of self-recognition and restraint of autoimmune assault. Such techniques
have been attempted in murine models of autoimmune disease including colitis (34)(35),
arthritis (36), and type 1 diabetes mellitus (IDDM) (37). In the case of arthritis and colitis,
injection of lymphotoxin-β receptor specific immunoglobulin fusion protein (LTβR Ig)
markedly reduces inflammation and physical symptoms in collagen-induced arthritis and
multiple models of experimentally induced colitis.

In IDDM, injection of LTβR Ig

prevented the usual onset of diabetes in non-obese diabetic (NOD) mice, and was able to
reverse islet destruction occurring in late stage autoimmune IDDM. Histologic analysis of
pancreata from LTβR-Ig treated mice revealed marked decrease in the prevalence of
lymphoid structures, suggesting that in this experiment, local lymphoid tissue played a role
in the disease-causing immunologic response to the nearby islet tissue.
Not all such enhanced antigen recognition may be detrimental. It has been demonstrated
that transgenic mice that are deficient in peripheral lymphoid tissue, yet express ectopic
lymphoid tissue in the lung (iBALT) in response to an infectious challenge, are able to
clear infection with a lesser degree of inflammation and damage to host tissue than wildtype mice (11). Many solid tumors display antigens that are distinct from normal tissue
proteins, yet the immune system fails to respond and mount an attack against these tissues.
It has been demonstrated that the cause of this failure to respond is immunologic ignorance
of the tumor antigens, due to a lack of presentation of antigen to lymphocytes. If ignorance
is broken, cytotoxic immune responses are actually quite effective in eliminating tumor
tissue (38). In an early demonstration of possible therapeutic use of ectopic lymphoid
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tissue, it has been demonstrated that if lymphotoxin-α is targeted to malignant tissue, the
resultant development of ectopic lymphoid tissue allows an improved T lymphocyte
response and, in murine models, has resulted in the complete eradication of pulmonary
tumors (39).
Another potential route to inducing tolerance in autoimmune disease or transplantation is
the development of a mechanism to target regulatory or suppressor T cells to ectopic
lymphoid organs, thus exerting a local inhibitory effect without requiring systemic
immunosuppression. In a murine model of cardiac allograft tolerance, regulatory T cells
(CD4+CD25+CD44highCD62Lhigh) were identified in peripheral lymph nodes of allograft
recipients made tolerant by either of two different tolerogenic regimens. Suppression of
lymph node homing by lymphocytes, induced by injection of anti-CD62L, prevented
regulatory T cell residence in lymph nodes and abrogated this induced tolerance. When
lymphocyte egress from lymph nodes was restricted by administration of FTY720,
regulatory T cell residency in peripheral lymph nodes and allograft tolerance were restored
(40). In a separate skin transplant assessment of regulatory T cell activity, transferred
CD4+CD25+ cells were noted to attenuate proliferation of graft-specific effector cells, with
marked reduction in CD4 replication occurring in draining lymph nodes (41). These studies
suggest that in addition to enabling allograft rejection, lymph nodes are the site for the
tolerance-promoting action of regulatory T cells, and that attention should be paid to both
regulatory as well as effector T cells in determining the net effect that tertiary lymphoid
organs may have upon target tissue.
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There remain questions about the identity of the specific cells that prompt the induction
of ectopic lymphoid tissue. Although multiple studies have confirmed the necessity of
signaling through the NF-κB pathway, and in many cases the LTβR, in the development of
both classic secondary lymphoid tissue as well as TLO, the source of the initiating cell
remains unclear (42). Hematopoietic CD4+CD3-IL-7Rαhi cells have been demonstrated to
play a role in the embryonic development of lymph nodes and Peyer’s patches, where they
have been noted to chemotax toward the chemokines ELC, SLC and BLC (CXCL13) (43).
Signaling through the IL-7Rα on these cells results in upregulation of LTα1β2, suggesting a
role as an inducer cell, activating the lymphogeneic pathways described earlier. In a
connection to ectopic lymphoneogenesis, it has been shown that the pancreatic tissue in
transgenic mice expressing a RIP-CXCL13 transgene contains a significant population of
CD4+CD3-IL-7Rαhi cells, suggesting that these cells may play a role in the formation of
ectopic, as well as native, lymphoid tissue(44), however details of this pathway are yet to
be fully elucidated.
There remains evidence that other cell types may also possess signaling mechanisms
relevant to the development of TLO. It has been demonstrated in ex-vivo studies that
activated, but not naïve, T cells express LTα1β2 (45). LTβ expression is induced in B cells
following antigen engagement and by chemokine (BLC) signaling, and it has been shown
that the absence of LT expressing B lymphocytes results in the inability of isolated
lymphoid follicles in the mucosal immune system to develop fully, suggesting that B cells
participate in the development of mucosal lymphoid tissue (46). Complicating matters is
the differential expression of chemokines by immune cells depending on their specific
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anatomic location. It has been shown that while mature dendritic cells in lymph nodes
strongly express the T cell chemoattractants SLC and ELC, mature dendritic cells residing
in ectopic lymphoid tissue formed during chronic inflammation do not express these
chemokines (47). Further research aimed at clarifying the nature of the inducer cell during
T cell mediated pathology is important to formulating approaches to modulate the
formation of tertiary lymphoid tissue.
Our data, which demonstrates that ectopic lymphoid tissue is sufficient to induce allograft
rejection in an aly/aly mouse, support the theory that ectopic lymphoid tissue has the
capacity to play a significant role in the alloimmune response. Further characterization of
the site of the alloimmune response may allow for more precise targeting of anti-rejection
therapy, thus improving the quality of life for those who rely on the failure of the immune
system to reject precious transplanted organs.
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